Estrella Immunopharma Bolsa (NASDAQ: ESLA)

Últimas noticias sobre Estrella Immunopharma (NASDAQ:ESLA) Bolsa

Estrella Immunopharma

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma Inc

Trading Ideas

Health In Tech Shares Resume Trade, Then Halted Again, This Time To The Downside

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Citigroup</strong>.</p>
<p>Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 22 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 59% with bearish.</p>
<p>From the overall spotted trades, 17 are puts, for a total amount of $1,338,929 and 5, calls, for a total amount of $403,959.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $57.5 to $77.5 for Citigroup over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Citigroup stands at 9225.15, with a total volume reaching 24,043.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Citigroup, situated within the strike price corridor from $57.5 to $77.5, throughout the last 30 days.</p>
<h3>Citigroup 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734970537_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.34</td>
<td>$2.22</td>
<td>$2.3</td>
<td>$77.50</td>
<td>$230.0K</td>
<td>4.4K</td>
<td>0</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.58</td>
<td>$2.57</td>
<td>$2.58</td>
<td>$60.00</td>
<td>$184.0K</td>
<td>26.1K</td>
<td>718</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$1.2</td>
<td>$1.16</td>
<td>$1.19</td>
<td>$70.00</td>
<td>$154.8K</td>
<td>2.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.7</td>
<td>$2.69</td>
<td>$2.7</td>
<td>$62.50</td>
<td>$153.1K</td>
<td>770</td>
<td>567</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.72</td>
<td>$2.71</td>
<td>$2.72</td>
<td>$62.50</td>
<td>$136.5K</td>
<td>770</td>
<td>567</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>Having examined the options trading patterns of Citigroup, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Citigroup's Current Market Status</h3>
<ul>
<li>With a volume of 1,896,254, the price of C is down -0.26% at $69.01. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 23 days.</li>
</ul>
<h3>Expert Opinions on Citigroup</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $83.25.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Citigroup with a target price of $90.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Citigroup, targeting a price of $80.<br />
&#x2A; Showing optimism, an analyst from Keefe, Bruyette &amp; Woods upgrades its rating to Outperform with a revised price target of $82.<br />
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Citigroup, which currently sits at a price target of $81. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Citigroup options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

A Closer Look at Citigroup's Options Market Dynamics

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Spotify Technology</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SPOT, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Spotify Technology.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 25% bullish and 43%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $684,088, and 8 are calls, for a total amount of $845,005.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $340.0 to $490.0 for Spotify Technology during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Spotify Technology's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Spotify Technology's whale trades within a strike price range from $340.0 to $490.0 in the last 30 days. </p>
<h3>Spotify Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734970532_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$40.75</td>
<td>$39.65</td>
<td>$40.28</td>
<td>$460.00</td>
<td>$402.8K</td>
<td align="right">909</td>
<td align="right">100</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$71.1</td>
<td>$70.0</td>
<td>$71.1</td>
<td>$490.00</td>
<td>$156.4K</td>
<td align="right">19</td>
<td align="right">57</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$132.75</td>
<td>$126.5</td>
<td>$130.75</td>
<td>$340.00</td>
<td>$130.7K</td>
<td align="right">55</td>
<td align="right">0</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$31.4</td>
<td>$30.3</td>
<td>$30.3</td>
<td>$480.00</td>
<td>$106.0K</td>
<td align="right">497</td>
<td align="right">123</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.15</td>
<td>$26.05</td>
<td>$27.15</td>
<td>$480.00</td>
<td>$86.8K</td>
<td align="right">497</td>
<td align="right">78</td>
</tr>
</tbody>
</table>
</p>
<h3>About Spotify Technology</h3>
<p>Spotify is the leading global music streaming service provider, with over 600 million monthly active users and 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.</p>
<p>After a thorough review of the options trading surrounding Spotify Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Spotify Technology's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 392,062, the SPOT's price is down by -1.31%, now at $454.83. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>Professional Analyst Ratings for Spotify Technology</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $560.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Spotify Technology, which currently sits at a price target of $560. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Spotify Technology options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SPOT

A Closer Look at Spotify Technology's Options Market Dynamics

<p>Financial giants have made a conspicuous bearish move on Snowflake. Our analysis of options history for Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) revealed 21 unusual trades.</p>
<p>Delving into the details, we found 23% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $149,740, and 17 were calls, valued at $1,233,994.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $210.0 for Snowflake over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Snowflake's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Snowflake's significant trades, within a strike price range of $65.0 to $210.0, over the past month.</p>
<h3>Snowflake Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734970527_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$25.6</td>
<td>$25.15</td>
<td>$25.35</td>
<td>$160.00</td>
<td>$134.3K</td>
<td>1.4K</td>
<td>114</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.65</td>
<td>$25.1</td>
<td>$25.28</td>
<td>$160.00</td>
<td>$128.9K</td>
<td>1.4K</td>
<td>61</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$59.5</td>
<td>$54.1</td>
<td>$56.9</td>
<td>$110.00</td>
<td>$113.8K</td>
<td>395</td>
<td>22</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.25</td>
<td>$21.3</td>
<td>$21.39</td>
<td>$200.00</td>
<td>$106.9K</td>
<td>4.5K</td>
<td>59</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$0.69</td>
<td>$0.68</td>
<td>$0.69</td>
<td>$190.00</td>
<td>$105.7K</td>
<td>8.6K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Snowflake</h3>
<p>Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.</p>
<p>In light of the recent options history for Snowflake, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Snowflake</h3>
<ul>
<li>Trading volume stands at 1,475,165, with SNOW's price down by -2.92%, positioned at $161.43.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 65 days.</li>
</ul>
<h3>What The Experts Say On Snowflake</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $195.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush has elevated its stance to Outperform, setting a new price target at $190.<br />
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $190.<br />
&#x2A; An analyst from Loop Capital persists with their Buy rating on Snowflake, maintaining a target price of $205.<br />
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Snowflake, maintaining a target price of $190.<br />
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Snowflake, which currently sits at a price target of $200. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Snowflake, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


SNOW

A Closer Look at Snowflake's Options Market Dynamics

DRCT

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 290.9%

<p><strong>Vertex Pharmaceuticals Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had <a href="https://www.benzinga.com/24/12/42599745/why-is-vertex-pharmaceuticals-stock-trading-on-thursday-lower-after-back-pain-trial-data">met its primary endpoint</a>.<strong></strong></p>
<p>The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.<strong></strong></p>
<p><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781dc5064ed0001730067/salveen-richter">Analyst Salveen Richter</a> maintained a Buy rating for Vertex Pharmaceuticals<strong> </strong>and price target of $602.</p>
<p><strong>The </strong><strong>Vertex Pharmaceuticals </strong><strong>Thesis:</strong> During the initial launch of Alyftrek, the company is likely to target those patients who had previously started on one of its CFTR modulators but have discontinued over time, Richter said in the note.</p>
<p>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.</p>
<p>Alyftrek expands the company's CF franchise to address around 6,000 such patients, he added.</p>
<p>Vertex Pharmaceuticals could also target patients who are currently on one of its other CF therapies, the analyst stated.</p>
<p>"Importantly, in addition to serving as a top-line growth opportunity, vanzacaftor enables higher margins and is dosed once daily, which provides incentive for switching notably in younger age groups," Richter wrote. This means Alyftrek provides the company with an "accretive opportunity" on both the top- and bottom-lines, he further said.</p>
<p><strong>VRTX Price Action:</strong> Shares of Vertex Pharmaceuticals<strong> </strong>had declined by 0.38% to $395.75 at the time of publication on Monday late morning.</p>
<p><strong>Read More: </strong><strong><a href="https://www.benzinga.com/news/large-cap/24/12/42638379/novo-nordisk-super-micro-computer-and-arm-are-among-top-large-cap-losers-last-week-december-16-20-are-the-others-in-your-portfolio">Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?</a></strong><strong></strong></p>



Analyst Color

Long Ideas

Reiteration

Analyst Ratings

VRTX

Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst

Health In Tech Shares Halted

<p>Roth MKM  analyst Mike Niehuser   maintains Tudor Gold (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/TUD#TSXV">TUD</a>) with a Buy and lowers the price target from C$3 to C$2.</p>


News

Price Target

TSXV:TUD

Roth MKM Maintains Buy on Tudor Gold, Lowers Price Target to C$2

IPOs

Health In Tech Shares Open For Trade At $5.25 Per Share; IPO Priced At $4.00 Per Share

<p><strong>MicroStrategy Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has further increased its holdings by purchasing 5,262 <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) at an average price of $106,662, totaling approximately $561 million.</p>
<p><strong>What Happened: </strong>This <a href="https://assets.contentstack.io/v3/assets/bltb564490bc5201f31/blt0ec5bb8a309ff033/67695cb1b1ed3c2aa7dc573e/form-8-k_12-23-2024.pdf">acquisition</a> brings MicroStrategy's total Bitcoin holdings to 444,262 BTC, with an average cost of $62,257 and a total cost of approximately $27.7 billion as of Dec. 22, 2024.</p>
<p>This latest purchase by MicroStrategy comes at a time of market speculation about a potential pause in their <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42617815/are-microstrategys-bitcoin-purchases-on-hold-in-january">Bitcoin-buying strategy next month</a>.</p>
<p>This speculation centers around the idea that the company might temporarily halt its practice of issuing convertible debt or selling shares through &#8220;at-the-market&#8221; programs to fund these acquisitions. </p>
<p>It is believed that these activities might be put on hold as the company prepares for the release of its earnings report in early February 2025. </p>
<p>A venture capitalist initially raised concerns about a potential restriction on the company issuing new convertible debt in January, which has spurred a great amount of discussion among investors.</p>
<p>While MicroStrategy has not confirmed or denied these rumors, it is generally understood that companies often implement self-imposed blackout periods to ensure compliance with trading regulations. </p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42647239/foresight-ventures-55m-investment-in-the-block-seeks-to-shape-the-future-of-crypto-media-forest-bai">Foresight Ventures&#8217; $55M Investment In The Block Seeks To Shape The Future Of Crypto Media: Forest Bai</a></strong></p>
<p>These periods usually occur near the end of a fiscal quarter and before the public release of earnings, thus limiting access to non-public information for insider trading purposes. </p>
<p>The SEC does not require these blackout periods, but companies implement them to maintain trust and integrity with the shareholders. </p>
<p>These financial blackout periods may apply to either ATM share sales, convertible debt offerings, or both and that information is not currently clear. </p>
<p>These potential restrictions on Bitcoin purchases have put a spotlight on MicroStrategy's funding strategies.</p>
<p>Some analysts believe the timing of the rumored blackout aligns with MicroStrategy&#8217;s upcoming earnings report between Feb. 3-5, 2025, and could be a result of common precautions that businesses adopt before publicly releasing financial information. </p>
<p>Furthermore, the company&#8217;s inclusion in the NASDAQ 100 index on Dec. 23 could also play a part, as this often leads companies to reassess their practices around governance and public disclosures. </p>
<p>Any decision about a blackout period is ultimately decided by MicroStrategy&#8217;s board of directors, reflecting the importance of regulatory adherence.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42644568/institutional-crypto-adoption-for-real-this-time-says-messari">Institutional Crypto Adoption &#8216;For Real This Time,&#8217; Says Messari</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Adds 5,262 Bitcoin To Bring Holdings To Over 444,000 BTC

NVDA

NVIDIA Option Alert: 4,353 Jan 17 $140 Calls Swept Near Ask At $5.651 With 128,293 Open Interest; Underlying Stock At $137.34

<p>Roth MKM  analyst Sean McGowan   maintains MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) with a Buy and lowers the price target from $65 to $60.</p>


MGPI

Roth MKM Maintains Buy on MGP Ingredients, Lowers Price Target to $60

<p>The Office of the Comptroller of the Currency (OCC) today issued a cease-and-desist order (order) against Bank of America, N.A. (bank) for deficiencies related to its Bank Secrecy Act (BSA) and sanctions compliance programs.</p>
<p><a href="https://occ.gov/news-issuances/news-releases/2024/nr-occ-2024-140.html" title="https://occ.gov/news-issuances/news-releases/2024/nr-occ-2024-140.html">https://occ.gov/news-issuances/news-releases/2024/nr-occ-2024-140.html</a></p>


'OCC Issues Cease and Desist Order Against Bank of America for BSA Deficiencies' - OCC

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 256.4%

<p>Financial giants have made a conspicuous bearish move on Applied Optoelectronics. Our analysis of options history for Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) revealed 21 unusual trades.</p>
<p>Delving into the details, we found 38% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $432,603, and 15 were calls, valued at $986,947.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $50.0 for Applied Optoelectronics during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Applied Optoelectronics's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Optoelectronics's whale activity within a strike price range from $22.5 to $50.0 in the last 30 days. </p>
<h3>Applied Optoelectronics Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969631_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$17.5</td>
<td>$16.5</td>
<td>$17.4</td>
<td>$22.50</td>
<td>$132.2K</td>
<td>1.7K</td>
<td align="right">46</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.5</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$35.00</td>
<td>$130.0K</td>
<td>2.8K</td>
<td align="right">205</td>
</tr>
<tr>
<td>AAOI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.4</td>
<td>$5.62</td>
<td>$35.00</td>
<td>$113.3K</td>
<td>2</td>
<td align="right">447</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$45.00</td>
<td>$97.5K</td>
<td>1.3K</td>
<td align="right">250</td>
</tr>
<tr>
<td>AAOI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.65</td>
<td>$35.00</td>
<td>$92.8K</td>
<td>2</td>
<td align="right">808</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Optoelectronics</h3>
<p>Applied Optoelectronics Inc is a provider of fiber-optic networking products for the Internet data center, cable television, telecommunications and fiber-to-the-home end markets. The company focuses on designing and manufacturing a range of optical communication products from components, to subassemblies, and modules to complete turn-key equipment. Demand for Applied Optoelectronics is driven by bandwidth demand in end markets. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The company derives maximum revenue from Taiwan.</p>
<p>In light of the recent options history for Applied Optoelectronics, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Applied Optoelectronics Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,020,369, the price of AAOI is down by -2.23%, reaching $36.98.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 59 days from now.</li>
</ul>
<h3>Expert Opinions on Applied Optoelectronics</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $34.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Northland Capital Markets downgraded its rating to Outperform, setting a price target of $40.<br />
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Applied Optoelectronics, maintaining a target price of $44.<br />
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Sell, adjusting the price target to $14.<br />
&#x2A; An analyst from Raymond James persists with their Outperform rating on Applied Optoelectronics, maintaining a target price of $39. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Applied Optoelectronics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AAOI

Applied Optoelectronics's Options Frenzy: What You Need to Know

<p>Financial giants have made a conspicuous bullish move on CrowdStrike Holdings. Our analysis of options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) revealed 19 unusual trades.</p>
<p>Delving into the details, we found 52% of traders were bullish, while 31% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $776,760, and 13 were calls, valued at $1,132,509.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $390.0 for CrowdStrike Holdings, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for CrowdStrike Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CrowdStrike Holdings's whale activity within a strike price range from $90.0 to $390.0 in the last 30 days. </p>
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969626_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$5.35</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$305.00</td>
<td>$518.5K</td>
<td>4</td>
<td>1.7K</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$160.5</td>
<td>$157.55</td>
<td>$158.05</td>
<td>$250.00</td>
<td>$316.1K</td>
<td>62</td>
<td>20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$148.45</td>
<td>$144.05</td>
<td>$146.75</td>
<td>$270.00</td>
<td>$293.5K</td>
<td>45</td>
<td>20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$81.8</td>
<td>$79.85</td>
<td>$81.8</td>
<td>$340.00</td>
<td>$89.9K</td>
<td>491</td>
<td>11</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.36</td>
<td>$1.35</td>
<td>$1.36</td>
<td>$300.00</td>
<td>$85.1K</td>
<td>5.0K</td>
<td>635</td>
</tr>
</tbody>
</table>
</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<p>Having examined the options trading patterns of CrowdStrike Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>CrowdStrike Holdings's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,143,560, the CRWD's price is down by -1.04%, now at $358.51. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 71 days.</li>
</ul>
<h3>Expert Opinions on CrowdStrike Holdings</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $398.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on CrowdStrike Holdings, which currently sits at a price target of $365.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on CrowdStrike Holdings with a target price of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on CrowdStrike Holdings with a target price of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on CrowdStrike Holdings with a target price of $450.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for CrowdStrike Holdings, targeting a price of $375. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CrowdStrike Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CRWD

Check Out What Whales Are Doing With CRWD

<p>Financial giants have made a conspicuous bearish move on Newmont. Our analysis of options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) revealed 17 unusual trades.</p>
<p>Delving into the details, we found 41% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $1,501,139, and 7 were calls, valued at $711,269.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $55.0 for Newmont over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Newmont stands at 2141.25, with a total volume reaching 3,328.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Newmont, situated within the strike price corridor from $35.0 to $55.0, throughout the last 30 days.</p>
<h3>Newmont Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969621_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$17.3</td>
<td>$17.15</td>
<td>$17.25</td>
<td>$55.00</td>
<td>$391.5K</td>
<td>118</td>
<td align="right">228</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$17.5</td>
<td>$17.4</td>
<td>$17.5</td>
<td>$55.00</td>
<td>$322.0K</td>
<td>118</td>
<td align="right">436</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$4.95</td>
<td>$6.0</td>
<td>$37.50</td>
<td>$300.6K</td>
<td>8.9K</td>
<td align="right">510</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.65</td>
<td>$8.55</td>
<td>$8.65</td>
<td>$45.00</td>
<td>$257.7K</td>
<td>4.8K</td>
<td align="right">302</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$42.50</td>
<td>$173.3K</td>
<td>3.1K</td>
<td align="right">300</td>
</tr>
</tbody>
</table>
</p>
<h3>About Newmont</h3>
<p>Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.</p>
<p>In light of the recent options history for Newmont, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Newmont</h3>
<ul>
<li>Currently trading with a volume of 1,927,050, the NEM's price is down by -1.89%, now at $37.55. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 59 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Newmont options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Newmont

<p>Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 28.92% on an annualized basis producing an average annual return of 39.92%. Currently, Tesla has a market capitalization of $1.37 trillion. </p>
<p><strong>Buying $1000 In TSLA:</strong> If an investor had bought $1000 of TSLA stock 10 years ago, it would be worth <strong>$28,316.31</strong> today based on a price of $425.27 for TSLA at the time of writing.</p>
<h3>Tesla's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734969609_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TSLA

$1000 Invested In Tesla 10 Years Ago Would Be Worth This Much Today

Trident Acquisitions Corp Units (1 Ord & 1 War)

TDACU

Trading Halt: Halt status updated at 11:00:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Loop Capital increased <strong>Microsoft Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $500 to $550. Loop Capital analyst Eric Beder maintained a Buy rating. Microsoft shares closed at $436.60 on Friday. See how other analysts view this stock.</li>
<li>Truist Securities cut the price target for <strong>Vertex Pharmaceuticals Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $550 to $460. Truist Securities analyst Joon Lee maintained a Buy rating. Vertex Pharmaceuticals shares closed at $397.27 on Friday. See how other analysts view this stock.</li>
<li>Goldman Sachs lowered the price target for <strong>Lennar Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $190 to $162. Goldman Sachs analyst Susan Maklari maintained a Neutral rating. Lennar shares closed at $138.08 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark boosted the price target for <strong>Humacyte, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) from $15 to $17. Benchmark analyst Bruce Jackson maintained a Buy rating. Humacyte shares closed at $4.64 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital <strong>Snowflake Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $185 to $205. Loop Capital analyst Mark Schappel maintained a Buy rating. Snowflake shares settled at $166.29 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital raised <strong>Uniti Group Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) price target from $5.5 to $6. RBC Capital analyst Bora Lee maintained a Sector Perform rating. Uniti shares closed at $5.70 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased <strong>Datadog, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $160 to $200. Loop Capital analyst Yun Kim maintained a Buy rating. Datadog shares closed at $149.46 on Friday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut the price target for <strong>Schlumberger Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from $60 to $59. Stifel analyst Stephen Gengaro maintained a Buy rating. Schlumberger shares settled at $36.83 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised <strong>Carnival Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) price target from $31 to $32. Barclays analyst Brandt Montour maintained an Overweight rating. Carnival shares closed at $26.80 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. increased <strong>SoundHound AI, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) price target from $8 to $26. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. SoundHound AI shares closed at $21.75 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


DDOG

HUMA

MSFT

SOUN

UNIT

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>We&rsquo;re starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!</p>



<p>Moving stocks are investments, acquisitions, new agreements and more.</p>



<p>Let&rsquo;s get into that news down</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Volcon </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/"><strong>VLCN</strong></a>) stock is rocketing more than 71% with heavy trading on <strong>Empery Asset Management, LP</strong> <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981363&amp;type=PDF&amp;symbol=VLCN&amp;cdn=0a561d788a48501f1c170c0f63b65ac5&amp;companyName=Volcon+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-01-11">taking a stake in the company</a>.</li>



<li><strong>Charge Enterprises</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/"><strong>CRGE</strong></a>) shares are soaring over 41% with strong early morning trading.</li>



<li><strong>Aeries Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aert-stock-quote/"><strong>AERT</strong></a>) stock is surging more than 35% alongside heavy trading this morning.</li>



<li><strong>Jet AI </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/"><strong>JTAI</strong></a>) shares are increasing over 20% as it also sees strong trading on Friday morning.</li>



<li><strong>Aileron Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/alrn-stock-quote/"><strong>ALRN</strong></a>) stock is gaining more than 18% following its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981539&amp;type=PDF&amp;symbol=ALRN&amp;cdn=2219d39279c110c1197b97762ea29d5d&amp;companyName=Aileron+Therapeutics+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-01-11">acquisition of Lung Therapeutics</a>.</li>



<li><strong>Hyperfine</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hypr-stock-quote/"><strong>HYPR</strong></a>) shares are heading over 16% higher without any clear news this morning.</li>



<li><strong>Akso Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ahg-stock-quote/"><strong>AHG</strong></a>) stock is climbing more than 14% today.</li>



<li><strong>Emcore </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/emkr-stock-quote/"><strong>EMKR</strong></a>) shares are jumping over 13% with a <a href="https://www.nasdaq.com/press-release/emcore-corporation-enters-into-cooperation-agreement-with-bradley-l.-radoff-2024-01">new cooperation agreement</a>.</li>



<li><strong>Apollomics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/"><strong>APLM</strong></a>) stock is rising more than 13% this morning.</li>



<li><strong>Safe &amp; Green Development</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/"><strong>SGD</strong></a>) shares are up over 13% on Friday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Estrella Immunopharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a>) stock is crashing more than 46% without any obvious news.</li>



<li><strong>Genius </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/"><strong>GNS</strong></a>) shares are plummeting over 34% after <a href="https://www.nasdaq.com/press-release/genius-group-announces-pricing-of-%248.25-million-public-offering-2024-01-12">pricing a public offering</a>.</li>



<li><strong>VCI Global</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcig-stock-quote/"><strong>VCIG</strong></a>) stock is diving more than 27% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317975438&amp;type=PDF&amp;symbol=VCIG&amp;cdn=d1e913c93adb43c9620f5e05d59906d8&amp;companyName=VCI+Global+Limited&amp;formType=F-1%2FA&amp;formDescription=%5BAmend%5D+Registration+statement+for+certain+foreign+private+issuers&amp;dateFiled=2024-01-08">a public offering</a>.</li>



<li><strong>SealSQ </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/laes-stock-quote/"><strong>LAES</strong></a>) shares are taking an over 20% beating <a href="https://www.globenewswire.com/news-release/2024/01/10/2807169/0/en/SEALSQ-Announces-FY-2023-Preliminary-Unaudited-Revenue-of-30-Million-Marking-a-29-Increase-Over-FY-2022.html">alongside preliminary earnings</a>.</li>



<li><strong>Future FinTech</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ftft-stock-quote/"><strong>FTFT</strong></a>) stock is tumbling more than 13% following <a href="https://www.marketwatch.com/story/future-fintech-stock-drops-13-after-sec-charges-ceo-68d81977">charges against its CEO</a>.</li>



<li><strong>Vivopower </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/"><strong>VVPR</strong></a>) shares are sliding over 12% after its <a href="https://www.marketwatch.com/story/vivopower-international-shares-rise-after-subsidiary-tembo-meets-milestones-for-strategic-direct-equity-investment-05502abe">subsidiary met certain milestones</a>.</li>



<li><strong>Tarena International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock is decreasing more than 11% this morning.</li>



<li><strong>MAIA Biotechnology</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/"><strong>MAIA</strong></a>) shares are dropping over 11% on Friday.</li>



<li><strong>Exicure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/"><strong>XCUR</strong></a>) stock is falling more than 9% without any news to report.</li>



<li><strong>Eightco </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/octo-stock-quote/"><strong>OCTO</strong></a>) shares close out our pre-market stock movers down close to 9%.</li>
</ol><p><em>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> that will provide high returns this year, with their new advances.</p>



<h2><strong>Catalyst Pharmaceuticals (CPRX)</strong></h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>


<p><strong>Catalyst Pharmaceuticals </strong>(NASDAQ<strong>:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/"><strong>CPRX</strong></a></strong>) is a pharmaceutical company that focuses on licensing the rights to the cures of rare diseases. It has a valuation of $<a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX">14.36</a>, with a YoY decrease of <a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX&amp;window=1Y">28.70%</a>. However, it appears to be poised for growth.</p>



<p>Although Catalyst has consistently <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">missed earnings estimates</a> by small margins, 4 <em>Yahoo Finance!</em> investors have given it a <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">buy rating</a>. Additionally, 5 analysts have given it a price target of <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">$26.20</a>, far above its current valuation. It has a debt of $3.64 million, with a free cash flow of $120.97 million. This gives it plenty of liquid assets to invest in the development of new drugs.</p>



<p>A few key drugs Catalyst has in its pipeline include drugs for <a href="https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fda-approval-agamreer">Duchenne muscular dystrophy</a>. This disease will have a market of <a href="https://www.alliedmarketresearch.com/duchenne-muscular-dystrophy-market-A15646">$2.07 billion in 2031</a>, with a CAGR of 4.7%. This is much more than Catalyst&rsquo;s current market cap of <a href="https://finance.yahoo.com/quote/CPRX/key-statistics?p=CPRX">$1.69 billion</a>, showing potential for future growth. Additionally, sales for current drugs are expected to hold steady. This makes it one of those biotech stocks to consider.</p>



<p>Management is expected to continue buying the rights to and developing drugs for niche, in-demand disorders. This opens the possibility of future growth. Coupled with being perceived as undervalued at the moment, it becomes clear why Catalyst Pharmaceuticals is a stock you should invest in.</p>



<h2><strong>Estrella Immunopharma (ESLA)&nbsp;</strong></h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>


<p><strong>Estrella Immunopharma </strong>(NASDAQ:<strong><a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a></strong>)<strong> </strong>is an American biopharmaceutical company focusing on the development of T-cell therapies. Headquartered in Emeryville, CA, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$1.03</a>.&nbsp;</p>



<p>Developing innovative therapies for solid tumors using novel &ldquo;mark-and-kill&rdquo; methods, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$62.67</a> &mdash; down 14.17% in the past month.</p>



<p>Valued at <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$36.26 millio</a>n, the biopharmaceuticals market size is estimated at $516.79 billion in 2024 and is expected to reach $761.80 billion by 2029, growing at a <a href="https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry">CAGR </a>of 8.07% during the forecast period.</p>



<p>Financially, ESLA improved on almost every metric during Q3 2023. ESLA reported <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$-1.87 million</a> in net income, a YoY increase of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">35.17%</a>. Total assets also received a massive surge of $27.35 million increasing over<a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX"> 750%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for ESLA, with the company outperforming previous years on net change in cash, increasing 1,886.80% YoY. This increase in liquidity makes it one of those biotech stocks for investors to pay close attention to.</p>



<p>ESLA is set up for success through recent <a href="https://www.estrellabio.com/pipeline">research</a> in novel drugs and therapies. It is developing advanced T-cell therapies, particularly focusing on its CD19-Redirected ARTEMIS T Cells. This approach is being applied initially to high-risk blood cancers. As ESLA continues to include an emphasis on research and development, expect ESLA valuation to climb as more customers gravitate towards the company&rsquo;s products.</p>



<h2><strong>VolitionRX (VNRX)</strong></h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


<p><strong>VolitionRX </strong>(NYSEAMERICAN:<strong><a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/"><strong>VNRX</strong></a></strong>)<strong> </strong>is a biotech company that takes part in the creation of blood-based cancer tests, helping diagnose a range of cancers. The company is based in Henderson, NV, and has amassed a valuation of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$0.86</a> with a strong increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">48.88%</a> in just the last month.&nbsp;&nbsp;</p>



<p>VNRX is fully established in the market but still shows signs of future growth. Valued at <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$67.94 million</a> in 2023, The global biotechnology market size accounted for $368 Billion in 2021 and is anticipated to reach $1,334 Billion by 2030 with a <a href="https://www.linkedin.com/pulse/biotechnology-market-anticipated-reach-usd-1334-billion/">CAGR </a>of 15.5%. </p>



<p>Financially, VNRX improved on almost every metric during Q3 2023. VNRX reported <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$165.21K</a> in revenue, a YoY increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">405.02%</a>. Net profit margin also received massive surges of $-5.07K, increasing over <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">70%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for VNRX, with the company YoY outperforming EPS by 23.64%.&nbsp;</p>



<p>VNRX is set up for success through recent<a href="https://finance.yahoo.com/news/volition-vpg-launch-nu-q-112400172.html"> announcements</a> of closing on an aggregate of $5.5 m<a href="https://finance.yahoo.com/news/volitionrx-secures-approximately-5-5-130000482.html">illion</a> in financing from investors at Wallonie Entreprendre in Belgium. It has also recently partnered with leading laboratories in the UK and Ireland to launch a groundbreaking cancer test for the early detection and monitoring of cancer in dogs. As VNRX continues to include an emphasis on innovation, expect VNRX valuation to climb as more investors and clients gravitate towards the company&rsquo;s services.</p>



<p><em>On the date of publication, Michael Que did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>The researchers contributing to this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Michael Que is a financial writer with extensive experience in the technology industry, with his work featured on Seeking Alpha, Benzinga and MSN Money. He is the owner of Que Capital, a research firm that combines fundamental analysis with ESG factors to pick the best sustainable long-term investments.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/01/next-big-thing-3-biotech-stocks-to-watch-for-groundbreaking-advances/">Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

Estrella Immunopharma (ESLA) has shared an update. Estrella Immunopharma, Inc. has recently updated their investor presentation on their website, w...

Estrella Immunopharma Unveils Updated Investor Presentation

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Estrella Immunopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a></span>) just reported results for the third quarter of 2024.</p><ul><li>Estrella Immunopharma reported earnings per share of -1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/esla-stock-earnings-estrella-immunopharma-for-q3-of-2024/">ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!</p>



<p>Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>VSee Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/"><strong>VSEE</strong></a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li><strong>Adagio Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/"><strong>ADGM</strong></a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li><strong>Akanda </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/"><strong>AKAN</strong></a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li><strong>Exicure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/"><strong>XCUR</strong></a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the <strong>Nasdaq Capital Market</strong>.</li>



<li><strong>Australian Oilseeds</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/"><strong>COOT</strong></a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li><strong>Tandem Diabetes Care</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/"><strong>TNDM</strong></a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li><strong>Vaccinex </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/"><strong>VCNX</strong></a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li><strong>AGBA Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/"><strong>AGBA</strong></a>) shares are climbing more than 13% without any clear news this morning.</li>



<li><strong>Venus Concept</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/"><strong>VERO</strong></a>) stock is jumping over 13% on Friday morning.</li>



<li><strong>Integral Ad Science</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/"><strong>IAS</strong></a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Gamer Pakistan</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/"><strong>GPAK</strong></a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li><strong>Fresh Vine Wine</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/"><strong>VINE</strong></a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li><strong>Conn&rsquo;s </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/"><strong>CONN</strong></a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li><strong>Greenlane </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/"><strong>GNLN</strong></a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li><strong>Procore Technologies</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/"><strong>PCOR</strong></a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li><strong>Estrella Immunopharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a>) shares are sliding close to 21% on Friday morning.</li>



<li><strong>Intel </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/"><strong>INTC</strong></a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li><strong>Smith Micro Software</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/"><strong>SMSI</strong></a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li><strong>GraniteShares 2x Long AMZN Daily ETF</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/"><strong>AMZZ</strong></a>) stock is slipping over 17%.</li>



<li><strong>Snap </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/"><strong>SNAP</strong></a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The latest announcement is out from Estrella Immunopharma (ESLA). Estrella Immunopharma, Inc. has appointed Ms. Hong Zhang as the new Chairperson a...

Estrella Immunopharma Welcomes New Chairperson, Expands Board

Estrella Immunopharma ( ($ESLA) ) just unveiled an update. Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO ...

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO

Estrella Immunopharma files for $100M common stock, warrants offering

17:11 EST Estrella Immunopharma (ESLA) files $100M common stock, warrants offering Published first on TheFly – the ultimate source for real-time, m...

Comments

Estrella Immunopharma

Noticias

Últimas noticias sobre Estrella Immunopharma (NASDAQ:ESLA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL